Adherence to a predefined vaccination program in patients with inflammatory bowel disease

Ruiz-Cuesta, Patricia; González-Alayón, Carlos; Jurado-García, Juan; Iglesias-Flores, Eva; Quintana, J.L. Barranco; García-García, Luisa; Salgueiro-Rodríguez, Isabel M.; Benitez-Cantero, José M.; García–Sánchez, Valle

doi:10.1016/j.gastre.2016.06.002

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 47 titles assessed for full-text screening, 10 were excluded for various reasons ( Supplementary Table S2 , available in the online version), 13 14 15 16 17 18 19 20 21 22 and eventually 37 papers were included in the systematic review. Fourteen studies were included in the analysis about baseline seroprevalence of hepatitis A in the setting of IBD, 23 24 25 26 27 28 29 30 31 32 33 34 35 36 5 studies reported on the seroconversion after complete HAV vaccination, 26 37 38 39 40 while 18 studies reported about the HAV vaccination rates in IBD patients 30 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 ( Tables 1 2 3 ).…”

Section: Resultsmentioning

confidence: 99%

Systematic Review and Meta-Analysis: Seroprevalence, Vaccination Rates, and Response for Hepatitis A in Inflammatory Bowel Disease

Jena,

Singh,

Neelam

et al. 2022

Journal of Gastrointestinal Infections

View full text Add to dashboard Cite

Introduction Guidelines recommend hepatitis A virus (HAV) vaccination in individuals with inflammatory bowel disease (IBD). We performed a systematic review to inform the clinical practice regarding this guidance. Methods After a PubMed and Embase search, duplicates were removed and the remaining titles screened for studies reporting relevant outcomes. Pooled seroprevalence rates for HAV, pooled vaccination rates, and pooled seroconversion rates were calculated. We also calculated pooled relative risk of seroprevalence for HAV among IBD and control population. Heterogeneity was investigated using subgroup analysis. Results The pooled seroprevalence of HAV antibodies in patients with IBD (14 studies, 2,370 patients) was 0.36 (95% confidence interval [CI]: 0.22–0.53, I 2 = 95%). On comparing the seroprevalence of HAV in IBD with controls (4 studies), the pooled relative risk was not different between the two (0.94, 95% CI: 0.66–1.34, I 2 = 76%). The pooled seroconversion rate after two doses of HAV vaccination (5 studies, 221 patients) was 0.93 (95% CI: 0.88–0.96, I 2 = 0%). Three studies (104 patients) reported on the seroconversion after a single dose of HAV vaccination and the pooled seroconversion rate was 0.47 (95% CI: 0.35–0.59, I 2 = 20%). The pooled vaccination rate for hepatitis A among patients with IBD (18 studies, 9,521 patients) was 0.21 (95% CI: 0.14–0.30, I 2 = 99%). Conclusion Hepatitis A vaccine has good immunogenicity in patients with IBD. The decision to routinely vaccinate IBD patients may be made in light of underlying seroprevalence of HAV.

show abstract

Section: Resultsmentioning

confidence: 99%

Systematic Review and Meta-Analysis: Seroprevalence, Vaccination Rates, and Response for Hepatitis A in Inflammatory Bowel Disease

Jena,

Singh,

Neelam

et al. 2022

Journal of Gastrointestinal Infections

View full text Add to dashboard Cite

show abstract

Issues of inflammatory bowel disease management in primary care.

Брынза¹,

Uvarova²

2021

Shidnoevr. z. vnutr. simejnoi med.

View full text Add to dashboard Cite

Іnflammatory bowel diseases are among various chronic processes, which, in the case of inadequate diagnosis and irrational treatment, eventually lead to highly unfavorable consequences. Thus, the timely establishment of the diagnosis, as well as the prescription of effective therapy and the subsequent careful follow-up of patients with inflammatory bowel diseases is the key to prolongation of the patients’ wellbeing and prevention of the occurrence of severe complications. Due to the possible increase in the prevalence of these pathologies in the future, close and effective cooperation between specialists and primary care physicians is extremely important nowadays. Unfortunately, there are currently no tools that can be used by primary care physicians to improve the routing of patients with inflammatory bowel disease. However, close and clear communication between primary and secondary healthcare specialists should become an integral part of health care systems, including that in our country.

show abstract

Adherence to a predefined vaccination program in patients with inflammatory bowel disease

Cited by 2 publications

References 23 publications

Systematic Review and Meta-Analysis: Seroprevalence, Vaccination Rates, and Response for Hepatitis A in Inflammatory Bowel Disease

Systematic Review and Meta-Analysis: Seroprevalence, Vaccination Rates, and Response for Hepatitis A in Inflammatory Bowel Disease

Issues of inflammatory bowel disease management in primary care.

Contact Info

Product

Resources

About